Neonatal lupus erythematous – A report of three cases by Chhajed, Punit S et al.
Vol 4 | Issue 4 | Oct - Dec 2017 Indian J Child Health 631
Case Report
Neonatal lupus erythematous – A report of three cases
Punit S Chhajed, S V Savaskar, N S Bhori, S T Bandichhode
Department of Pediatrics, Dr. V.M. Government Medical College & S.C.S.M. General Hospital, Solapur, Maharashtra, India
Correspondence to: Dr. Punit S Chhajed, Department of Pediatrics, Dr. V.M. Government Medical College & S.C.S.M. General 
Hospital, Vasantdada Patil Chowk, Opp. District Court, Solapur - 413 003, Maharashtra, India. Phone: +91-9870510050/7507060078. 
Email: drpunitchhajed29@gmail.com
Received – 25 July 2017 Initial Review – 14 August 2017   Published Online – 10 September 2017
Neonatal lupus erythematosus (NLE) is a rare, acquired autoimmune disorder. It is associated with transplacental transport of maternal anti-Ro/SS-A and/or anti-La/SS-B 
and/or anti U1 ribonucleoprotein (RNP) antibodies into fetal 
circulation. It is characterized by skin lesions and/or cardiac 
complications in the newborn, which coexist in only 10% of 
patients [1]. Less commonly, hepatic, hematological, pulmonary, 
neurological, and gastrointestinal abnormalities may also be 
present. The maternal connective tissue disorder in most of the 
cases is systemic lupus erythematosus or Sjogren syndrome. 
Approximately 50% of the mothers are asymptomatic at the time 
of diagnosis of NLE in their off springs; testing positive only 
against Ro/La and/or U1 RNP autoantibodies [2]. We describe 
three cases of NLE with cutaneous, cardiac and coexistent 
cutaneous, and cardiac manifestations.
CASE REPORTS
Case 1 - Cutaneous manifestation
A 2-day-old preterm (32 weeks) euthermic and hemodynamically 
stable female baby was referred to the neonatal intensive care 
unit (NICU) for rash over face, scalp, and trunk since birth. 
Erythematous, scaly plaques were present over scalp, trunk, 
and face with “raccoon eyes” or “owl eyed” appearance and 
telangiectatic lesions were seen on the trunk (Figs. 1 and 2). Rest 
of the examination was normal. Mother had a history of fever since 
2nd month of gestation, associated with progressive photosensitive 
rash, oral and lip ulcers, and joint aches. Her investigations 
revealed microcytic hypochromic anemia and raised erythrocyte 
sedimentation rate. Her serum tested positive for ANA 
(index 3.2) (index <1.0 = negative, index 1.0-1.2 = borderline, 
index >1.2 = positive), anti-dsDNA (140.07 IU/ml) (negative 
<25, borderline 25-34.9, weakly positive 35-99.9, moderately 
positive 100-200, strongly positive >200), anti-Ro-52, anti-
SS-B, and anti-U1RNP antibodies (qualitative assay). Baby’s 
serum had antibodies against nRNP/Sm and Rib P-protein. 
Electrocardiogram (ECG), two-dimensional (2D) echocardiogram 
(ECHO), and other laboratory investigations of the baby were 
normal. Skin lesions faded over 2 weeks and cleared by 40th day 
of life, leaving behind hypopigmented atrophic macules (Figs. 3 
and 4). She did not develop any cardiac complications, required 
no further treatment, and continues to thrive well.
Case 2 - Cardiac manifestation
A 2.4 kg, female child born to a 20-year-old primigravida by lower 
segment cesarian section (LSCS) at 35 weeks of gestation in view 
of fetal bradycardia. Mother was registered and immunized, had 
two antenatal checkups; however, no ultrasonography was done. 
She had an uneventful antenatal period. Baby cried well after birth, 
was pink in color, and had good tone and reflex activity. Her heart 
rate was 50 beats/min and thus, admitted to NICU. She was active, 
euthermic and was accepting breast feeds. Laboratory investigations 
were normal. Her ECG revealed a 2:1 heart block (Fig. 5). On 2nd 
day of life, bradycardia persisted and a grade II ejection systolic 
murmur was heard over left 2nd intercostal space. ECHO showed a 
3 mm patent ductus arteriosus (PDA) with left to right shunt with 
congenital heart block. Sera of mother and baby tested positive 
for anti Ro/SS-A and La/SS-B antibodies. Baby was advised for 
regular follow-up to assess the need of pacemaker implantation. At 
2 month age, baby was thriving well with an average heart rate of 
48–50 beats/min but was subsequently lost to follow-up. 
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Case 3 - Cardiac and cutaneous manifestation
A 2 kg female child delivered at term by LSCS in view of fetal 
bradycardia. Baby was admitted to the NICU with a postnatal 
heart rate 40 beats/min. Her skin showed flat, erythematous, non-
blanching, non-scaly papules over forehead and glabella with 
violaceous hue to both upper eyelids (Fig. 6). ECG revealed a 
(3:1) complete heart block (CHB) (Fig. 7). 2D ECHO showed 
no structural defects. Mother was asymptomatic and had no 
antenatal complaints. Ultrasonography at 33 weeks gestation was 
suggestive of intrauterine growth retardation and mildly reduced 
amniotic fluid. Sera of mother and baby showed the presence of 
anti Ro/SS-A and anti La/SS-B antibodies. The baby succumbed 
due to cardiac arrest on 7th day of life. 
DISCUSSION
NLE is a rare acquired autoimmune disorder present in newborn 
infants of mothers with autoantibodies against Ro, La, and less 
commonly U1-RNP mainly characterized by skin lesions and/
or cardiac complications. Generally, when patients have skin 
manifestations, they have no cardiac defects and vice versa; 
however, in 10% of cases, these manifestations may coexist [1]. 
Other findings may involve hematological, hepatic, and rarely 
neurological manifestations. The incidence of NLE has been 
estimated as 1 in 20,000 live births [3]. The female-male ratio in 
large studies has been 1:1, but some studies have suggested a 3:1 
ratio [4]. No racial predilection has been observed. 
The precise mechanism of injury to specific tissues, such as 
skin and heart, is not known. The available evidence points strongly 
to autoantibodies as the cause of NLE. The transitory nature of 
manifestations that coincides with disappearance of IgG antibodies 
circulating in infant’s blood tends to confirm this hypothesis [5]. 
Other significant etiological factors (both maternal and fetal) 
contributing to tissue injury in NLE are currently ill defined, but 
twin studies suggest that they are likely to be both genetic and 
environmental [6]. Ultraviolet (UV) light exposure may precipitate 
and/or exacerbate cutaneous lesions of NLE, but the presence of 
lesions at birth indicates that UV light is not essential for disease 
expression. Genes of MHC and C4 have been identified as 
contributors to NLE [7]. There is emerging evidence that tumor 
necrosis factor α and transforming growth factor β polymorphisms 
may contribute in determining which babies exposed to maternal 
anti-Ro/SS-A will be affected and which will not [8].
Figure 1: Erythematous scaly plaques in periorbital region giving 
“raccoon eyes” appearance
Figure 2: Telangiectatic lesion over epigastrium and scaly papules 
over neck
Figure 3: Healed rash at day of life 40. Note the hypopigmentation in 
periorbital and malar region, identical to the pattern of erythematous 
rash
Figure 4: Rash and telangiectatic lesions disappeared leaving behind 
atrophic macules
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The maternal connective tissue disorder has been SLE or 
Sjogren syndrome in most cases. Approximately 50% of mothers 
are asymptomatic at the time of diagnosis testing positive only 
against Ro/La and/or U1RNP autoantibodies. With time, most 
of the mothers develop some symptoms of autoimmunity. The 
recurrence rate of NLE in subsequent pregnancies has been 
estimated to be 16-24% [9]. Cutaneous lesions represent the most 
common manifestation of NLE. Characteristic lesions are transient 
non-scarring, photosensitive, erythematous, annular macules, 
papules, and/or plaques with or without fine scaling. There is a 
predilection for face and scalp, particularly the periorbital region, 
resulting in so-called “owl’s eye” or “raccoon eyes” (periorbital 
erythema) appearance seen in 80% of the cutaneous NLE cases. 
Saoji and Deopujari [10] reported three cases of NLE with 
skin lesions since birth. The skin lesions varied from annular 
lesions in one, purpura in the other, and hypopigmented atrophic 
patches on the face and upper trunk in the third case. ECHO was 
normal in all the three cases indicating no cardiac involvement. 
Sawant et al. [11] reported a case of anti-Ro-positive cutaneous 
lupus erythematosus with an uncommon skin manifestation 
in the form of erythematous annular plaques with scaling on 
the extremities, palms, and soles with periorbital erythema 
and edema giving the characteristic “eye mask” or “owl’s eye” 
appearance. Disease activity resolves spontaneously in few 
weeks or months, but dyspigmentation, residual telangiectasia, 
and mild atrophic scarring may persist for months to years. Skin 
biopsy is not always performed owing to the age of the child and 
the predilection of lesions for the face. Protection form UV light 
and use of sunscreen is imperative. Mild topical steroids may be 
used; however, spontaneous resolution is the natural course of 
these lesions. 
Congenital CHB is the second most common clinical feature 
of NLE. Isolated CHB occurs in approximately 1 in 20,000 
births and of these cases; an estimated 88% may be attributed 
to NLE. Heart block is thought to result from deposition of anti-
SS-A/Ro antibody at the atrioventricular node, which leads to 
fibrosis and calcification. It usually appears in fetus from 16 to 
20 weeks of gestation. In 90% of the cases, it is seen by birth. 
The CHB is irreversible and in approximately two-third children, 
it requires permanent pacemaker implantation and is associated 
with a substantial mortality of 20-30% [4]. Normal sinus rhythm 
in utero can progress to CHB in 7 days. The best treatment for 
CHB is prevention as once it has occurred treatment seems to be 
unsuccessful. CHB (and usually second degree block) results in 
fetal bradycardia that can be detected by routine fetal auscultation 
or ultrasonography between 18 and 24 weeks of gestation. A 
weekly scan starting 16 weeks is advisable [6]. The incidence 
increases 5-10 folds in mothers who already have a child with 
NLE. Hence, mothers with baby affected by NLE should be serially 
monitored in subsequent pregnancies. Use of dexamethasone and 
fluorinated corticosteroids to prevent/treat heart block in utero is 
not supported by evidence [12] and is precluded by its side effects 
in fetus and mother. 
For high-risk mothers, having a previous child with CHB, a 
multinational open-label study is currently underway to confirm 
or refuse efficacy of intravenous immunoglobulin in preventing 
CHB [13]. A case–control study suggests that hydroxychloroquine 
may decrease the risk of cardiac lupus related to anti-SSA/
SSB antibodies, but prospective studies are needed for its 
confirmation [14]. Postnatal diagnosis is done by testing sera 
of mother and fetus for anti-Ro/SSA antibodies in the setting of 
Figure 5: Electrocardiogram showing a heart rate of 46 beats/min with a 2:1 heart block
Figure 6: Note the flat, non-scaling erythematous papules over 
forehead and glabella with violaceous hue to both upper eyelids
Figure 7: Electrocardiogram, lead II showing heart rate 42 beats/min 
and complete (3:1) heart block
Vol 4 | Issue 4 | Oct - Dec 2017 Indian J Child Health 634
Chhajed et al. Neonatal lupus erythematosus
CHB confirmed by an ECG, with or without symptoms in mother. 
An ECHO should be done to rule out structural heart defects. 
Cardiomyopathy is the second most common cardiac abnormality 
commonly in the presence of CHB. Other cardiac problems 
include subendocardial fibroelastosis, fibrinous pericarditis, and 
PDA. 
The diagnosis of NLE is established from characteristic clinical 
findings and identification of above-mentioned autoantibodies 
in the mother and child. The prognosis of disease is defined by 
the cardiac involvement as most of the other manifestations are 
transitory and self-resolving. These children are at increased risk 
of developing autoimmune disease in late childhood or adulthood. 
The literature on long-term follow-up of NLE babies is limited but 
four out of 57 infants in the NLE research registry with cutaneous 
NLE followed up for a mean period of 77 months (1-204 months) 
developed autoimmune disease in the form of juvenile rheumatoid 
arthritis (two children), Hashimoto’s thyroiditis (one child), and 
Raynaud’s phenomenon (one child), and there are case reports of 
SLE developing in teenage years [15].
CONCLUSION
NLE is a rare acquired autoimmune disorder which presents with 
transient cutaneous manifestations or as irreversible congenital 
heart block and cardiomyopathy. Prognosis is defined by cardiac 
involvement. Diagnosis is based on clinical manifestation and 
serologic testing for anti Ro/SS-A, anti La/SS-B, and/or anti U1 
RNP in mother and infant.
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